Potent inhibitory effects of resveratrol derivatives on progression of prostate cancer cells

Archiv der Pharmazie

Volumn 339, Issue 5, 2006, Pages 238-241

  Yoo, Kyung Mi ^a   Kim, Sanghee ^b   Moon, Bo Kyung ^c   Kim, Sung Soo ^a   Kim, Kyung Tack ^a   Kim, Sun Yeou ^d   Choi, Sang Yoon ^a  

^a Korea Food Research Institute   (South Korea)

^b Seoul National University   (South Korea)

^c Chung Ang University   (South Korea)

^d Kyung Hee University   (South Korea)

Author keywords

LNCaP; PC 3; Prostate cancer; Resveratrol derivative

Indexed keywords

(3,5 DIMETHOXYBENZYLIDENE) (2,4 DIMETHOXYPHENYL)AMINE; 3,5,2',4' TETRAMETHOXYSTIBENE; 3,5,4' TRIMETHOXYSTILBENE; 4 [2 (3,5 DIMETHOXYPHENYL) VINYL]PYRIDINE; ANTINEOPLASTIC AGENT; N (2,4 DIMETHOXYPHENYL) 3,5 DIMETHOXY BENZAMIDE; RESVERATROL; STILBENE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL STRAIN LNCAP; DRUG EFFECT; DRUG INHIBITION; DRUG SYNTHESIS; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; HUMANS; MALE; PROSTATIC NEOPLASMS; STILBENES; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 33744461613     PISSN: 03656233     EISSN: 15214184     Source Type: Journal    
DOI: 10.1002/ardp.200500228     Document Type: Article

References (14)

1. M. Careri, C. Corradini, L. Elviri, I. Nicoletti, I. Zagnoni, J. Agric. Food Chem. 2004, 52, 6868-6874.
2. N. H. Shin, S. Y. Ryu, E. J. Choi, S. H. Kang, I. M. Chang, K. Min, Y. Kim, Biochem. Biophys. Res. Commun. 1998, 243, 801-803.
3. D. K. Das, M. Sato, P. S. Ray, G. Maulik, R. M. Engelman, A. A. Bertelli, A. Bertelli, Drugs. Exp. Clin. Res. 1999, 25, 115-120.
4. L. Fremont, Life Sci. 2000, 66, 663-673.
5. J. M. Wu, Z. R. Wang, T. C. Hsieh, J. L. Bruder, J. G. Zou, Y. Z. Huang, Int. J. Mol. Med. 2001, 8, 3-17.
6. J. F. Savouret, M. Quesne, Biomed. Pharmacother. 2002, 56, 84-87.
7. I. Zoberi, C. M. Bradbury, H. A. Curry, K. S. Bisht, P. C. Goswami, J. L. Roti, D. Gius, Cancer Lett. 2002, 375, 165-173.
8. Y. J. Surh, Y. J. Hurh, J. Y. Kang, E. Lee, G. Kong, S. J. Lee, Cancer Lett. 1999, 240, 1-10.
9. T. Walle, F. Hsieh, M. H. Delegge, J. E. Jr. Oatis, U. K. Walle, Drug. Metab. Dispos., 2004, 32, 1377-1382.
10. M. Asensi, I. Medina, A. Ortega, J. Carretero, M. Carmen, E. Obrador, J. M. Estrela, Free Radic. Biol. Med. 2002, 33, 387-398.
11. H. H. Juang, M. L. Hsieh, K. H. Tsui, J. Mol. Endocrinol 2004, 33, 121-132.
12. S. Kim, H. Ko, J. E. Park, S. Jung, S. K. Lee, Y. Chun, J. Med. Chem. 2002, 45, 160-164.
13. B. J. Feldman, D. Feldman, Not. Rev. Canc. 2001, 1, 34-45.
14. R. Agarwal, Biochem. Pharmacol. 2001, 60, 1051-1059.